uniQure 将来の成長

Future 基準チェック /26

uniQureは、17.1%と35.8%でそれぞれ年率17.1%で利益と収益が成長すると予測される一方、EPSはgrowで21.3%年率。

主要情報

17.1%

収益成長率

21.3%

EPS成長率

Biotechs 収益成長	42.4%
収益成長率	35.8%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	07 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:UQ1 - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	93	-126	-80	-71	10
12/31/2025	41	-141	-53	-83	13
12/31/2024	39	-194	-157	-152	13
9/30/2024	29	-240	-185	-179	N/A
6/30/2024	28	-285	-111	-104	N/A
3/31/2024	19	-297	-135	-128	N/A
12/31/2023	16	-308	-153	-146	N/A
9/30/2023	112	-228	-161	-151	N/A
6/30/2023	112	-187	-251	-239	N/A
3/31/2023	110	-157	-214	-198	N/A
12/31/2022	106	-127	-163	-145	N/A
9/30/2022	61	-125	-154	-137	N/A
6/30/2022	62	-114	-149	-129	N/A
3/31/2022	525	324	286	304	N/A
12/31/2021	524	330	271	288	N/A
9/30/2021	500	321	281	298	N/A
6/30/2021	500	303	292	303	N/A
3/31/2021	38	-139	-154	-143	N/A
12/31/2020	38	-125	-144	-135	N/A
9/30/2020	6	-166	-132	-124	N/A
6/30/2020	5	-136	-120	-111	N/A
3/31/2020	6	-124	-114	-105	N/A
12/31/2019	7	-124	-105	-99	N/A
9/30/2019	6	-105	-96	-91	N/A
6/30/2019	8	-103	-93	-89	N/A
3/31/2019	9	-92	-86	-81	N/A
12/31/2018	11	-83	-80	-76	N/A
9/30/2018	12	-90	-81	-76	N/A
6/30/2018	11	-78	N/A	-71	N/A
3/31/2018	13	-78	N/A	-74	N/A
12/31/2017	13	-79	N/A	-64	N/A
9/30/2017	20	-67	N/A	-62	N/A
6/30/2017	25	-72	N/A	-65	N/A
3/31/2017	24	-71	N/A	-68	N/A
12/31/2016	25	-73	N/A	-72	N/A
9/30/2016	20	-76	N/A	-81	N/A
6/30/2016	16	-90	N/A	-62	N/A
3/31/2016	14	-90	N/A	5	N/A
12/31/2015	11	-82	N/A	7	N/A
9/30/2015	8	-76	N/A	22	N/A
6/30/2015	6	-58	N/A	13	N/A
3/31/2015	5	-45	N/A	-35	N/A
12/31/2014	6	-50	N/A	-37	N/A
9/30/2014	5	-41	N/A	-29	N/A
6/30/2014	6	-42	N/A	-6	N/A
3/31/2014	6	-41	N/A	-7	N/A
12/31/2013	4	-37	N/A	-6	N/A

アナリストによる今後の成長予測

収入対貯蓄率: UQ1今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: UQ1今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: UQ1今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: UQ1の収益 ( 35.8% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: UQ1の収益 ( 35.8% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: UQ1の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

uniQure 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2021

No longer forecast to breakeven

Recent updates

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

Third quarter 2024 earnings released: US$0.91 loss per share (vs US$1.88 loss in 3Q 2023)

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of Amt-162 for the Treatment Sod1-ALS

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$1.16 loss per share (vs US$1.44 loss in 2Q 2023)

Uniqure N.V. Announces Executive Changes

Now 22% overvalued

New minor risk - Shareholder dilution

First quarter 2024 earnings released: US$1.36 loss per share (vs US$1.63 loss in 1Q 2023)

uniQure N.V., Annual General Meeting, Jun 18, 2024

New minor risk - Shareholder dilution

Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director

CEO & Executive Director recently sold €163k worth of stock

Full year 2023 earnings released: US$6.47 loss per share (vs US$2.71 loss in FY 2022)

uniQure N.V. Announces Update on Phase I/II Clinical Trials of Amt-130Gene Therapy for the Treatment of Huntington's Disease

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for Amt-191 Gene Therapy for Fabry Disease

Now 25% undervalued after recent price drop

Third quarter 2023 earnings released: US$1.88 loss per share (vs US$1.02 loss in 3Q 2022)

New major risk - Revenue and earnings growth

uniQure N.V. Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

Second quarter 2023 earnings released: US$1.44 loss per share (vs US$0.84 loss in 2Q 2022)

uniQure N.V. Announces Executive Changes

New major risk - Share price stability

First quarter 2023 earnings released: US$1.63 loss per share (vs US$1.00 loss in 1Q 2022)

CEO & Executive Director recently sold €465k worth of stock

Full year 2022 earnings released: US$2.71 loss per share (vs US$7.17 profit in FY 2021)

CEO & Executive Director recently sold €142k worth of stock

uniQure N.V. Highlights Therapeutic Potential of Amt-260 in Refractory Temporal Lobe Epilepsy (Rtle) At Virtual Research & Development Event

Insufficient new directors

Third quarter 2022 earnings released: US$1.02 loss per share (vs US$0.79 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.84 loss per share (vs US$8.68 profit in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

uniQure N.V. Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

Chief Operating Officer recently sold €95k worth of stock

uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review

uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review

First quarter 2022 earnings released: US$1.00 loss per share (vs US$0.91 loss in 1Q 2021)

uniQure N.V., Annual General Meeting, Jun 14, 2022

Insufficient new directors

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

CEO & Executive Director recently sold €152k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease

CEO & Executive Director recently sold €175k worth of stock

Investor sentiment deteriorated over the past week

uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

Insufficient new directors

Investor sentiment improved over the past week

Third quarter 2021 earnings released: US$0.79 loss per share (vs US$1.21 loss in 3Q 2020)

President of Research & Development recently sold €271k worth of stock

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS US$8.68 (vs US$0.96 loss in 2Q 2020)

Independent Non-Executive Chairman Philip Astley-Sparke has left the company

uniQure N.V. (NasdaqGS:QURE) entered into a definitive agreement to acquire Corlieve Therapeutics SAS for €250 million.

Independent Non-Executive Chairman Philip Astley-Sparke has left the company

uniQure N.V. Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

uniQure N.V. Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

Forecast to breakeven in 2021

No longer forecast to breakeven

uniQure N.V. Presents Hope-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Antibodies to Aav5 Vector

First quarter 2021 earnings released: US$0.91 loss per share (vs US$0.63 loss in 1Q 2020)

uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program

CEO, CFO & Executive Director recently sold €152k worth of stock

Full year 2020 earnings released: US$2.81 loss per share (vs US$3.11 loss in FY 2019)

Revenue misses expectations

New 90-day low: €28.63

uniQure N.V. Announces Positive Recommendation from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

Chief Accounting Officer recently sold €261k worth of stock

New 90-day low: €30.00